AQST is trading 5.6% down at $4.71 in pre-market, extending the weakness seen in the June 24 after-hours session as regulatory and legal overhangs persist.
- The stock continues to face pressure from securities-fraud class action headlines and lingering concerns over FDA-identified deficiencies.
- While the move follows a Complete Response Letter for the Anaphylm NDA, there is no fresh, company-specific news this morning clearly tied to the current price action.